NEW YORK (GenomeWeb) – MDxHealth announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to Qiagen for use in its QIAsure assay, a CE-marked test for use in differentiating patients' risk of developing cervical cancer.

Under the terms of the agreement, MDxHealth will receive a signing fee plus royalties from future test sales utilizing the technology.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.